Drug
Diquafosol tetrasodium clinical trials
Keep track of what changes. Save the diquafosol tetrasodium studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2023 (4)
| Year | Studies |
|---|---|
| 1999 | 1 |
| 2000 | 1 |
| 2001 | 2 |
| 2005 | 1 |
| 2022 | 2 |
| 2023 | 4 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 7
He Eye Hospital (6) · Merck Sharp & Dohme LLC (5) · Santen Pharmaceutical Co., Ltd. (2) · Indonesia University (1)
Studies
Open first, then newest update. How each study uses diquafosol tetrasodium is read from its arms, and is right about nine times in ten.
Testing it · 14
- Effects of 3% Diquafosol on Tear Film and Vision-related Quality of Life in Orthokeratology Lens Related Dry EyeNot yet recruitingNot applicableHe Eye HospitalNCT06537349Written as 3% Diquafosol tetrasodium
- Effectiveness of Diquafosol Prophylactic Therapy to Prevent Dry Eye Disease for Cataract Surgery Patients in IndonesiaRecruitingPhase 2Indonesia UniversityNCT06146881Written as Diquafosol sodium 3%
- Diquafosol vs Hyaluronic Acid for Diabetic Dry EyeCompletedNot applicableHe Eye HospitalNCT05682547Written as 3% Diquafosol tetrasodium
- Management of DE With IPL in Combination With DQSCompletedNot applicableHe Eye HospitalNCT05694026Written as Diquafosol tetrasodium
- Temperature on Evaporative Dry EyeStatus unknownNot applicableHe Eye HospitalNCT05720754Written as Diquafosol tetrasodium
- Diquafosol Ophthalmic Solution for Dry Eye SymptomsStatus unknownNot applicableHe Eye HospitalNCT04980144Written as 3% Diquafosol tetrasodium
- Use of 3% Diquafosol Topical Ophthalmic Solution for Diabetic Dry EyeStatus unknownNot applicableHe Eye HospitalNCT05193331Written as 3% Diquafosol tetrasodium
- Study of INS365 Ophthalmic Solution in Subjects With Dry Eye DiseaseCompletedPhase 3Merck Sharp & Dohme LLCNCT00404131Written as diquafosol tetrasodium (INS365) Ophthalmic Solution
- Study of INS365 Ophthalmic Solution in Subjects With Dry Eye DiseaseCompletedPhase 3Merck Sharp & Dohme LLCNCT00403715Written as diquafosol tetrasodium (INS365) Ophthalmic Solution
- A Double-masked, Randomized, Placebo-controlled,Pilot Study of Diquafosol Tetrasodium in Subjects Following Photorefractive Keratectomy (PRK)TerminatedPhase 2Merck Sharp & Dohme LLCNCT01381731Written as diquafosol tetrasodium ophthalmic solution 2%
- A Study of INS365 Ophthalmic Solution in Patients With Moderate to Severe Dry Eye DiseaseCompletedPhase 2Merck Sharp & Dohme LLCNCT00679718Written as diquafosol tetrasodium (INS365) ophthalmic solution
- A Study to Determine the Safety and Tolerability of Escalating Doses of INS365 Ophthalmic SolutionCompletedPhase 2Merck Sharp & Dohme LLCNCT00680108Written as diquafosol tetrasodium (INS365) ophthalmic solution
- Phase III Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry EyeCompletedPhase 3Santen Pharmaceutical Co., Ltd.NCT01240382Written as 3% DE-089 ophthalmic solution
- Late Phase II Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry EyeCompletedPhase 2Santen Pharmaceutical Co., Ltd.NCT01189032Written as DE-089 ophthalmic solution
As the comparator · 1 — what is tested is compared with diquafosol tetrasodium
Codes
What other systems call diquafosol tetrasodium · ClinicalTrials.gg INT018447
- UNII (FDA) X8T9SBH9LLDIQUAFOSOL TETRASODIUMConfirmed FDA, Wikidata
- Wikidata Q27293698diquafosol tetrasodiumConfirmed FDA, Wikidata
- NCI Thesaurus C65437Diquafosol TetrasodiumOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | X8T9SBH9LL | DIQUAFOSOL TETRASODIUM | Confirmed FDA, Wikidata |
| Wikidata | Q27293698 | diquafosol tetrasodium | Confirmed FDA, Wikidata |
| NCI Thesaurus | C65437 | Diquafosol Tetrasodium | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.